Fida Biosystems welcomes Swedish Fåhraeus Startup and Growth Fund (FSG) as a new investor, while EIFO strengthens its commitment to the Danish innovator.
Fida Biosystems, a Danish life science tools company, has raised €5 million from EIFO and Swedish venture fund FSG to further accelerate growth.
The company has developed a biophysical analysis platform for molecular and nanoparticle characterization to be conducted more quickly and accurately, ultimately speeding up the development of new medicines.
Over the past year, the company has doubled its revenue, and with more than 100 instruments sold, it is seeing increased adoption across industry and leading research institution.
The new investment is an extension of a previous series A round and is intended to prepare Fida Biosystems for a future Series B growth round, paving the way for further expansion and scaling.
“As we close a year marked by more than double growth, we are pleased to complete a new round led by FSG, with continued support from EIFO and our other investors. With our amended team, we are confident that we are in the best possible position to continue supporting researchers in developing faster and better drugs - and to further accelerate the company’s growth,” said Brian Sørensen, CEO of Fida Biosystems.
At EIFO, Tonni Bülow-Nielsen, Partner at EIFO’s team for Direct Life Science Investment, is pleased to participate in the round. EIFO first invested in Fida Biosystems in 2019 and this follow-on investment underscores EIFO’s strategic ambition to strengthen Denmark’s position in transformative technologies and life science.
“Fida’s technology aligns perfectly with EIFO’s focus on innovation that drives growth. We have strong confidence in the team and are pleased to support the company’s further expansion and scaling, reinforcing Denmark’s role in life science,” said Tonni Bülow-Nielsen.
At FSG, Linus Wiebe, General Partner and Managing Director, is delighted to announce its participation in the Series A financing round.
“With FSG’s focus on Scandinavian companies at the cross-section of Technology and Life Science we are proud to invest in FidaBio and its unique first principle technology for biophysical analysis for the Pharma and Biotech industry. We look forward to work hard with the Fidabio team and EIFO as lead investors in this next phase of growth” said Linus Wiebe.
About Fida Biosystems
Fida Biosystems develops advanced analytical platforms based on its proprietary Flow Induced Dispersion Analysis (FIDA) technology. This innovation enables rapid and precise analysis of biomolecules and nanoparticles directly in complex biological samples, helping biotech and pharmaceutical companies better understand molecular behavior and accelerate drug development.
Over the past year, the company has doubled its revenue, and with more than 100 instruments sold, it is seeing increased adoption across industry and leading research institution.
About FSG
Fåhraeus Startup & Growth FSG Fund II (FSG) is a leading Nordic venture capital fund specializing in supporting high-impact startups and growth-stage companies in technology and life sciences. FSG combines strategic investments with deep industry expertise to empower transformative innovations.
